Second Annual Global Champions of Change Competition Winner

MMS has just concluded its second annual Global Champions of Change Competition (G3C), where colleagues from all MMS regions submitted innovative ideas based on our tradition of providing high-quality, efficient services to our clients to help discover and market life-changing medicines to patients around the world.  

Innovation is not new to MMS, we have designed our culture from the beginning to constantly strive for new and better ways to produce quality with efficiency. The G3C competition was created two years ago as a formal way to spark the sharing of innovative ideas from colleagues throughout the entire organization in a competitive but fun environment.  

This year’s G3C winner is Amanda Beaster, Senior Manager of Regulatory Strategy, for her submission of a tool to address labeling deficiencies in the pharmaceutical industry.  

The second-place winners are Audelia Munguia, Director of Safety Risk Management; Susan Mitcheson, Senior Safety Writer; Jeff Wiese, Technical Manager of Safety Writing; and Katrina O’Connor, Senior Medical Writer, for their submission aimed to enhance efficiencies and quality in aggregate reports.  

Thirty-one teams entered this year’s competition, and five teams were chosen to proceed to the final presentation round, with our global colleagues voting for the winner. All 31 entries are evaluated and considered for future implementation.  

Other submissions included ideas that included automation, improving processes, data visualization, supporting rare diseases, improving quality, and concepts relating to MMS technologies such as our TrialAssure Transparency Suite and Datacise.  

MMS believes that innovation comes directly from our colleagues at every level of the organization because those working in our services lines daily see the best opportunities for improvement, and are encouraged to bring those ideas forward. That’s why we often say that “innovation is a company sport”. The G3C competition is not the only time our colleagues can bring innovative ideas forward, and MMS colleagues are encouraged to submit their ideas for improvement throughout the year.   

We are so proud of our colleagues and the effort, energy, and excitement they exhibited during this competition and through their work on a daily basis.  

By Jim Balcom, Director of Partnerships and IT Governance 

Learn more and explore MMS career opportunities here.  

Contact us to speak with Jim Balcom to learn more about innovation.  

Suggested For You

perspectives

September 29th, 2026

Getting to First-in-Human Faster: What FDA’s New IND Pilot and NAMs Shift Mean for Sponsors

perspectives

September 21st, 2026

From Data to Decisions: Evaluating Bayesian Dynamic Borrowing Before Your Trial Begins

perspectives

September 11th, 2026

Navigating the Future of Clinical Trial Transparency: Balancing AI-Driven Anonymization with Human Oversight 

perspectives

September 3rd, 2026

From Signal to System: FDA Approval Does Not Mean Treatment Can Begin the Next Morning

perspectives

August 27th, 2026

Risk-Based Data Management: Moving Beyond Traditional Data Cleaning

perspectives

August 17th, 2026

From Signal to System: The Evidence Questions Psychedelic Therapies Must Answer

perspectives

August 11th, 2026

The Race to Faster Drug Development: A Quicker On-Ramp Doesn’t Help If You’re Headed the Wrong Way 

perspectives

August 7th, 2026

UK Clinical Trial Transparency Changes for Phase I Studies: What Sponsors Need to Know

perspectives

July 31st, 2026

FDA Orphan Drug Designation Requirements: Key Mistakes to Avoid

perspectives

July 29th, 2026

From Signal to System: The Next Challenges for Psychedelic Therapies

perspectives

July 24th, 2026

FDA’s Latest Psychedelic Guidance: Key Changes and Implications for Sponsors

perspectives

July 7th, 2026

Don’t Veer for Deer: Why Drug Development Needs Steady Steering in the Age of AI and Real-Time Data